TMDX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TMDX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
TransMedics Group's Issuance of Debt for the three months ended in Sep. 2024 was $0.0 Mil.
TransMedics Group's Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2024 was $0.0 Mil.
The historical data trend for TransMedics Group's Issuance of Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TransMedics Group Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Issuance of Debt | Get a 7-Day Free Trial | - | 2.25 | - | 58.51 | 445.38 |
TransMedics Group Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Issuance of Debt | Get a 7-Day Free Trial | - | - | - | - | - |
Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.
Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of TransMedics Group's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.
Tamer I Khayal | officer: Chief Commercial Officer | TRANSMEDICS INC, 200 MINUTEMAN ROAD, ANDOVER MA 01810 |
Edward M Basile | director | 200 MINUTEMAN ROAD, ANDOVER MA 01810 |
Waleed H Hassanein | director, officer: President & CEO | TRANSMEDICS INC, 200 MINUTEMAN ROAD, ANDOVER MA 01810 |
Nicholas Corcoran | officer: See Remarks | C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810 |
James R Tobin | director | C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
Anil P. Ranganath | officer: See Remarks | C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810 |
Stephen Gordon | officer: Chief Financial Officer | 200 MINUTEMAN ROAD, ANDOVER MA 01810 |
David Weill | director | 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810 |
Miriam Provost | officer: VP of US Regulatory & FDA Rel. | 2000 MINUTEMAN ROAD, ANDOVER MA 01810 |
John F Carey | officer: VP of Operations | 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810 |
Laura Damme | officer: VP, Clinical Affairs | C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810 |
Stephanie Lovell | director | C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142 |
Kania Edwin M Jr | director | |
Rakesh P. Godhani | officer: Chief Digital Officer | C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810 |
John F Sullivan | officer: VP of Quality & Engineering | 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810 |
From GuruFocus
By GuruFocus News • 10-29-2024
By GuruFocus News • 11-11-2024
By GuruFocus News • 11-28-2024
By GuruFocus News • 10-04-2024
By Marketwired • 10-29-2024
By GuruFocus News • 10-29-2024
By GuruFocus News • 10-07-2024
By GuruFocus News • 12-05-2024
By GuruFocus News • 11-22-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.